Related Experiment Video
Updated: Jun 27, 2025
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Prognostic gene biomarkers for c-Src inhibitor Si162 sensitivity in melanoma cells
Seyhan Türk1, Ayşegül Yilmaz2, Ümit Yavuz Malkan3
1Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Ankara, Turkiye.
Background/Aim:
Early detection and treatment are crucial in combating malignant melanoma. Src is an important therapeutic target in melanoma due to its association with cancer progression. However, developing effective Src-targeting drugs remains challenging and personalized medicine relies on biomarkers and targeted therapies for precise and effective treatment. This study focuses on Si162, a newly synthesized c-Src inhibitor, to identify reliable biomarkers for predicting Si162 sensitivity and explore associated biological characteristics and pathways in melanoma cells.
Materials And Methods:
Primary melanoma cells (M1, M21, M24, M84, M133, M307, and M2025) were obtained from patients diagnosed with melanoma. Si162 cytotoxicity tests were performed using luminescent adenosine triphosphate detection and the half-maximal inhibitory concentration (IC50) values were calculated. Gene expression profiles were analyzed using microarray-based gene expression data. Differentially expressed genes between the resistant and sensitive groups were identified using Pearson correlation analysis. Gene coexpression, interactions, and pathways were investigated through clustering, network, and pathway analyses. Biological functions were examined using the Database for Annotation, Visualization, and Integrated Discovery. Molecular pathways associated with different responses to Si162 were identified using gene set enrichment analysis. The gene expressions were validated using reverse transcription-quantitative polymerase chain reaction.
Results:
The cells revealed significant differences in response to Si162 based on the IC50 values (p < 0.05). A total of 36 differentially expressed genes associated with Si162 susceptibility were identified. Distinct expression patterns between the sensitive and resistant groups were observed in 9 genes (LRBA, MGMT, CAND1, ADD1, SETD2, CNTN6, FGF18, C18orf25, and RPL13). Coexpression among the differentially expressed genes was highlighted, and 9 genes associated with molecular pathways, including EMT, transforming growth factor-beta (TGF-β) signaling, and ribosomal protein synthesis, between groups. Genes involved in dysregulated immune response were observed in the resistant group. The involvement of 5 genes (ADD1, CNTN6, FGF18, C18orf25, and RPL13) in Si162 resistance was confirmed through qRT-PCR validation.
Conclusion:
These findings contribute to our understanding of the underlying biological differences among melanoma cells and suggest potential biomarkers and pathways associated with Si162 response and resistance.
Insights
This study identifies 9 key genes associated with melanoma cell sensitivity to the c-Src inhibitor Si162. These findings reveal potential biomarkers and pathways for predicting treatment response in melanoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant melanoma requires early detection and targeted therapies.
- Src kinase is a key therapeutic target in melanoma progression.
- Developing effective Src inhibitors and predictive biomarkers is crucial for personalized medicine.
Purpose of the Study:
- To identify biomarkers predicting sensitivity to the novel c-Src inhibitor Si162 in melanoma cells.
- To explore biological characteristics and pathways associated with Si162 response and resistance.
- To advance targeted therapy strategies for melanoma.
Main Methods:
- Primary melanoma cells were treated with Si162, and cytotoxicity was assessed via IC50 values.
- Gene expression profiling was conducted using microarrays.
- Differential gene expression, coexpression, network, and pathway analyses were performed.
- Gene expression was validated using reverse transcription-quantitative polymerase chain reaction (qRT-PCR).
Main Results:
- Significant differences in Si162 sensitivity were observed across melanoma cell lines (p < 0.05).
- 36 differentially expressed genes were linked to Si162 susceptibility, with 9 showing distinct patterns between sensitive and resistant groups.
- Key pathways identified include Epithelial-Mesenchymal Transition (EMT), transforming growth factor-beta (TGF-β) signaling, and ribosomal protein synthesis.
- Five genes (ADD1, CNTN6, FGF18, C18orf25, and RPL13) were validated as involved in Si162 resistance.
Conclusions:
- Distinct gene expression profiles correlate with Si162 sensitivity in melanoma cells.
- Identified genes and pathways offer potential biomarkers for predicting Si162 efficacy.
- Understanding these molecular differences can guide the development of more effective melanoma treatments.
